List view / Grid view
16 May 2024 | By Drug Target Review
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint…
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
Many exciting developments are expected to take place in immunotherapy and oncology in the next few years. We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments,…
New immunotherapies may be developed for patients with HCC associated with steatotic liver disease, with TREM1 suggested as a target.
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
